<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Wockhardt Limited — News on 6ix</title>
<link>https://6ix.com/company/wockhardt-limited</link>
<description>Latest news and press releases for Wockhardt Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 30 Mar 2026 12:58:06 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/wockhardt-limited" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683650fa78dffbe2df155851.webp</url>
<title>Wockhardt Limited</title>
<link>https://6ix.com/company/wockhardt-limited</link>
</image>
<item>
<title>Press Release Mar 30 2026</title>
<link>https://6ix.com/company/wockhardt-limited/news/press-release-mar-30-2026-4</link>
<guid isPermaLink="true">https://6ix.com/company/wockhardt-limited/news/press-release-mar-30-2026-4</guid>
<pubDate>Mon, 30 Mar 2026 12:58:06 GMT</pubDate>
<description>Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release -"Wockhardt's Zaynich® (Zidebactam/Cefepime) Receives Favourable Recommendation from CDSCO's Subject Expert Committee for Treatment of Gram-Negative Infections".</description>
</item>
<item>
<title>Press Release Feb 10 2026</title>
<link>https://6ix.com/company/wockhardt-limited/news/press-release-feb-10-2026-18</link>
<guid isPermaLink="true">https://6ix.com/company/wockhardt-limited/news/press-release-feb-10-2026-18</guid>
<pubDate>Tue, 10 Feb 2026 20:04:14 GMT</pubDate>
<description>Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the quarter and nine months ended 31st December, 2025.</description>
</item>
<item>
<title>Press Release Jan 27 2026</title>
<link>https://6ix.com/company/wockhardt-limited/news/press-release-jan-27-2026-9</link>
<guid isPermaLink="true">https://6ix.com/company/wockhardt-limited/news/press-release-jan-27-2026-9</guid>
<pubDate>Tue, 27 Jan 2026 14:05:29 GMT</pubDate>
<description>Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release Wockhardt s Fifth Novel Antibiotic, Foviscu® (WCK 4282), Matches Gold-Standard Meropenem in pivotal Phase 3 Trial as First-Line Therapies Fail Against Rising Resistance .</description>
</item>
<item>
<title>Press Release Jan 07 2026</title>
<link>https://6ix.com/company/wockhardt-limited/news/press-release-jan-07-2026-4</link>
<guid isPermaLink="true">https://6ix.com/company/wockhardt-limited/news/press-release-jan-07-2026-4</guid>
<pubDate>Wed, 07 Jan 2026 14:04:33 GMT</pubDate>
<description>Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release - Wockhardt Files Marketing Authorisation Application for WCK 5222 with European Medicines Agency.</description>
</item>
<item>
<title>Press Release Dec 31 2025</title>
<link>https://6ix.com/company/wockhardt-limited/news/press-release-dec-31-2025</link>
<guid isPermaLink="true">https://6ix.com/company/wockhardt-limited/news/press-release-dec-31-2025</guid>
<pubDate>Wed, 31 Dec 2025 17:34:06 GMT</pubDate>
<description>Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release European Medicines Agency Grants Accelerated Assessment to WCK 5222 ".</description>
</item>
<item>
<title>Press Release Dec 01 2025</title>
<link>https://6ix.com/company/wockhardt-limited/news/press-release-dec-01-2025-8</link>
<guid isPermaLink="true">https://6ix.com/company/wockhardt-limited/news/press-release-dec-01-2025-8</guid>
<pubDate>Mon, 01 Dec 2025 16:39:40 GMT</pubDate>
<description>Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release US FDA Accepts Wockhardt s New Drug Application for Breakthrough Antibiotic Zaynich .</description>
</item>
<item>
<title>Press Release Nov 03 2025</title>
<link>https://6ix.com/company/wockhardt-limited/news/press-release-nov-03-2025-7</link>
<guid isPermaLink="true">https://6ix.com/company/wockhardt-limited/news/press-release-nov-03-2025-7</guid>
<pubDate>Mon, 03 Nov 2025 20:35:24 GMT</pubDate>
<description>Wockhardt Limited has informed the Exchange regarding a press release dated November 03, 2025, titled "Submission pursuant to Regulation 30 of SEBI (Listing Obligations and DisclosureRequirements) Regulations, 2015 ( Listing Regulations ) - Press Release".</description>
</item>
<item>
<title>Press Release Oct 01 2025</title>
<link>https://6ix.com/company/wockhardt-limited/news/press-release-oct-01-2025-5</link>
<guid isPermaLink="true">https://6ix.com/company/wockhardt-limited/news/press-release-oct-01-2025-5</guid>
<pubDate>Wed, 01 Oct 2025 13:02:33 GMT</pubDate>
<description>Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release Wockhardt Submits New Drug Application to U.S. FDA for Zidebactam-Cefepime (WCK 5222) for Treatment of Serious Gram-Negative Infections .</description>
</item>
<item>
<title>Press Release Sep 25 2025</title>
<link>https://6ix.com/company/wockhardt-limited/news/press-release-sep-25-2025-6</link>
<guid isPermaLink="true">https://6ix.com/company/wockhardt-limited/news/press-release-sep-25-2025-6</guid>
<pubDate>Thu, 25 Sep 2025 20:16:54 GMT</pubDate>
<description>Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release Prestigious Medical and Public Health Journal THE LANCET Regional Health Publishes Pivotal Phase 3 Clinical Study on Miqnaf® (Nafithromycin) A Landmark for India s Antibiotic Innovation .</description>
</item>
<item>
<title>Press Release Aug 08 2025</title>
<link>https://6ix.com/company/wockhardt-limited/news/press-release-aug-08-2025-8</link>
<guid isPermaLink="true">https://6ix.com/company/wockhardt-limited/news/press-release-aug-08-2025-8</guid>
<pubDate>Fri, 08 Aug 2025 19:08:45 GMT</pubDate>
<description>Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2025.</description>
</item>
<item>
<title>Press Release Jul 28 2025</title>
<link>https://6ix.com/company/wockhardt-limited/news/press-release-jul-28-2025-12</link>
<guid isPermaLink="true">https://6ix.com/company/wockhardt-limited/news/press-release-jul-28-2025-12</guid>
<pubDate>Mon, 28 Jul 2025 13:02:19 GMT</pubDate>
<description>Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release Leading U.K. Medical Journal publishes a Complex Case of Severe Pan-drug Resistant Infection in U.S. LiverTransplant Patient Successfully Treated with Zaynich® (Zidebactam/Cefepime, WCK 5222) .</description>
</item>
<item>
<title>Press Release Jul 11 2025</title>
<link>https://6ix.com/company/wockhardt-limited/news/press-release-jul-11-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/wockhardt-limited/news/press-release-jul-11-2025-1</guid>
<pubDate>Fri, 11 Jul 2025 20:08:52 GMT</pubDate>
<description>Wockhardt Limited has informed the Exchange regarding a press release dated July 11, 2025, titled "Wockhardt Initiates Strategic Realignment of US Operations to Focus on Innovative Portfolio .</description>
</item>
<item>
<title>Press Release May 29 2025</title>
<link>https://6ix.com/company/wockhardt-limited/news/press-release-may-29-2025-5</link>
<guid isPermaLink="true">https://6ix.com/company/wockhardt-limited/news/press-release-may-29-2025-5</guid>
<pubDate>Thu, 29 May 2025 21:30:07 GMT</pubDate>
<description>Wockhardt Limited has informed the Exchange regarding a press release dated May 29, 2025, titled "Press Release on the Audited Financial Results (Standalone and Consolidated) for the quarter and the financial year ended 31st March, 2025".</description>
</item>
<item>
<title>Press Release Apr 01 2025</title>
<link>https://6ix.com/company/wockhardt-limited/news/press-release-apr-01-2025-11</link>
<guid isPermaLink="true">https://6ix.com/company/wockhardt-limited/news/press-release-apr-01-2025-11</guid>
<pubDate>Tue, 01 Apr 2025 13:05:38 GMT</pubDate>
<description>Wockhardt Limited has informed the Exchange regarding a press release dated April 01, 2025, titled Paediatric US Cancer Patient with Recalcitrant Blood and Liver Infection Successfully Treated with Zaynich (Zidebactam/Cefepime, WCK 5222)"</description>
</item>
<item>
<title>Press Release Feb 07 2025</title>
<link>https://6ix.com/company/wockhardt-limited/news/press-release-feb-07-2025-5</link>
<guid isPermaLink="true">https://6ix.com/company/wockhardt-limited/news/press-release-feb-07-2025-5</guid>
<pubDate>Fri, 07 Feb 2025 21:31:45 GMT</pubDate>
<description>Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the quarter and nine months ended 31st December, 2024</description>
</item>
<item>
<title>Press Release Jan 31 2025</title>
<link>https://6ix.com/company/wockhardt-limited/news/press-release-jan-31-2025-15</link>
<guid isPermaLink="true">https://6ix.com/company/wockhardt-limited/news/press-release-jan-31-2025-15</guid>
<pubDate>Fri, 31 Jan 2025 13:58:18 GMT</pubDate>
<description>Wockhardt Limited has informed the Exchange regarding a press release dated January 31, 2025, titled Wockhardt s Zaynich? (Zidebactam/Cefepime, WCK 5222) achieves highest-ever efficacy meeting superiority in a global, pivotal, registration-enabling Phase III study in complicated urinary tract infection (cUTI) achieving 96.8% clinical cure rate ".</description>
</item>
<item>
<title>Press Release Jan 13 2025</title>
<link>https://6ix.com/company/wockhardt-limited/news/press-release-jan-13-2025-7</link>
<guid isPermaLink="true">https://6ix.com/company/wockhardt-limited/news/press-release-jan-13-2025-7</guid>
<pubDate>Mon, 13 Jan 2025 13:59:43 GMT</pubDate>
<description>Wockhardt Limited has informed the Exchange regarding a press release dated January 13, 2025, titled Zaynich? (Zidebactam/Cefepime, WCK 5222) achieves over 97% Efficacy in Clinical Study for serious infections caused by Meropenem-Resistant Gram-Negative Pathogens .".</description>
</item>
<item>
<title>Press Release Jan 02 2025</title>
<link>https://6ix.com/company/wockhardt-limited/news/press-release-jan-02-2025-3</link>
<guid isPermaLink="true">https://6ix.com/company/wockhardt-limited/news/press-release-jan-02-2025-3</guid>
<pubDate>Fri, 03 Jan 2025 00:16:24 GMT</pubDate>
<description>Wockhardt Limited has informed the Exchange regarding a press release dated January 02, 2025, titled "Indian Drug Regulator Approves Wockhardt's New Generation Oral Antibiotic Miqnaf? (Nafithromycin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)."</description>
</item>
<item>
<title>Press Release Dec 16 2024</title>
<link>https://6ix.com/company/wockhardt-limited/news/press-release-dec-16-2024-3</link>
<guid isPermaLink="true">https://6ix.com/company/wockhardt-limited/news/press-release-dec-16-2024-3</guid>
<pubDate>Mon, 16 Dec 2024 14:06:25 GMT</pubDate>
<description>Wockhardt Limited has informed the Exchange regarding a press release dated December 16, 2024, titled "Zaynich (Zidebactam/Cefepime, WCK 5222) enables US cancer patient undergo successful liver transplant and resume chemotherapy by eradicating dual extreme-drug resistant Gram negative pathogens".</description>
</item>
<item>
<title>Press Release Nov 13 2024</title>
<link>https://6ix.com/company/wockhardt-limited/news/press-release-nov-13-2024-10</link>
<guid isPermaLink="true">https://6ix.com/company/wockhardt-limited/news/press-release-nov-13-2024-10</guid>
<pubDate>Wed, 13 Nov 2024 22:50:31 GMT</pubDate>
<description>Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2024.</description>
</item>
</channel>
</rss>